156 related articles for article (PubMed ID: 23581155)
1. The FDA's regulatory role in the ICCVAM process.
Schechtman LM; Stokes WS
Altern Lab Anim; 2004 Jun; 32 Suppl 1B():663-8. PubMed ID: 23581155
[TBL] [Abstract][Full Text] [Related]
2. Implementation of the 3Rs (refinement, reduction, and replacement): validation and regulatory acceptance considerations for alternative toxicological test methods.
Schechtman LM
ILAR J; 2002; 43 Suppl():S85-94. PubMed ID: 12388858
[TBL] [Abstract][Full Text] [Related]
3. The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM): a review of the ICCVAM test method evaluation process and current international collaborations with the European Centre for the Validation of Alternative Methods (ECVAM).
Stokes WS; Schechtman LM; Hill RN
Altern Lab Anim; 2002 Dec; 30 Suppl 2():23-32. PubMed ID: 12513648
[TBL] [Abstract][Full Text] [Related]
4. ICCVAM evaluation of the murine local lymph node assay. The ICCVAM review process.
Sailstad DM; Hattan D; Hill RN; Stokes WS
Regul Toxicol Pharmacol; 2001 Dec; 34(3):249-57. PubMed ID: 11754529
[TBL] [Abstract][Full Text] [Related]
5. A new path forward: the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM).
Casey W; Jacobs A; Maull E; Matheson J; Clarke C; Lowit A
J Am Assoc Lab Anim Sci; 2015 Mar; 54(2):170-3. PubMed ID: 25836963
[TBL] [Abstract][Full Text] [Related]
6. Skin sensitization testing needs and data uses by US regulatory and research agencies.
Strickland J; Daniel AB; Allen D; Aguila C; Ahir S; Bancos S; Craig E; Germolec D; Ghosh C; Hudson NL; Jacobs A; Lehmann DM; Matheson J; Reinke EN; Sadrieh N; Vukmanovic S; Kleinstreuer N
Arch Toxicol; 2019 Feb; 93(2):273-291. PubMed ID: 30377734
[TBL] [Abstract][Full Text] [Related]
7. The status of eye irritancy testing: a regulatory perspective.
Wilcox NL
Lens Eye Toxic Res; 1992; 9(3-4):259-71. PubMed ID: 1301785
[TBL] [Abstract][Full Text] [Related]
8. Validation and regulatory acceptance of alternatives.
Hill RN; Stokes WS
Camb Q Healthc Ethics; 1999; 8(1):73-9. PubMed ID: 9924621
[No Abstract] [Full Text] [Related]
9. The safety assessment process--setting the scene: an FDA perspective.
Schechtman LM
ILAR J; 2002; 43 Suppl():S5-10. PubMed ID: 12388844
[TBL] [Abstract][Full Text] [Related]
10. ECVAM-ICCVAM: prospects for future collaboration.
Schechtman LM; Stokes WS
Altern Lab Anim; 2002 Dec; 30 Suppl 2():227-36. PubMed ID: 12513682
[TBL] [Abstract][Full Text] [Related]
11. United States regulatory requirements for skin and eye irritation testing.
Choksi NY; Truax J; Layton A; Matheson J; Mattie D; Varney T; Tao J; Yozzo K; McDougal AJ; Merrill J; Lowther D; Barroso J; Linke B; Casey W; Allen D
Cutan Ocul Toxicol; 2019 Jun; 38(2):141-155. PubMed ID: 30418044
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Acute Oral Systemic Toxicity Using a Multifingerprint Similarity Approach.
Alberga D; Trisciuzzi D; Mansouri K; Mangiatordi GF; Nicolotti O
Toxicol Sci; 2019 Feb; 167(2):484-495. PubMed ID: 30371864
[TBL] [Abstract][Full Text] [Related]
13. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
14. Validating new toxicology tests for regulatory acceptance.
Zeiger E; Stokes WS
Regul Toxicol Pharmacol; 1998 Feb; 27(1 Pt 1):32-7. PubMed ID: 9629594
[TBL] [Abstract][Full Text] [Related]
15. Meeting report: Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use.
Corvi R; Ahr HJ; Albertini S; Blakey DH; Clerici L; Coecke S; Douglas GR; Gribaldo L; Groten JP; Haase B; Hamernik K; Hartung T; Inoue T; Indans I; Maurici D; Orphanides G; Rembges D; Sansone SA; Snape JR; Toda E; Tong W; van Delft JH; Weis B; Schechtman LM
Environ Health Perspect; 2006 Mar; 114(3):420-9. PubMed ID: 16507466
[TBL] [Abstract][Full Text] [Related]
16. Validating new toxicology tests for regulatory acceptance.
Zeiger E; Stokes WS
Regul Toxicol Pharmacol; 1998 Feb; 27(1 Pt 2):32-7. PubMed ID: 9618321
[TBL] [Abstract][Full Text] [Related]
17. Update on the validation and regulatory acceptance of alternative tests for skin corrosion and irritation.
Fentem JH; Botham PA
Altern Lab Anim; 2004 Jun; 32 Suppl 1B():683-8. PubMed ID: 23581159
[TBL] [Abstract][Full Text] [Related]
18. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
19. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
20. Predictive Models for Acute Oral Systemic Toxicity: A Workshop to Bridge the Gap from Research to Regulation.
Kleinstreuer NC; Karmaus A; Mansouri K; Allen DG; Fitzpatrick JM; Patlewicz G
Comput Toxicol; 2018 Nov; 8(11):21-24. PubMed ID: 30320239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
